Western blot analysis results showed that the p-PI3K/PI3K and p-Akt/Akt expression levels in the PA-treated group were lower than those in the control group, indicating that PA could effectively inhibit the activation of the PI3K/Akt pathway in osteosarcoma cells. The gene discussed is AKT1; the disease is osteosarcoma.